Allogeneic cord blood–derived NK cells are engineered with a chimeric antigen receptor that binds Claudin 18.2 on tumor cells, activating NK cytotoxic programs to induce perforin/granzyme-mediated lysis and cytokine secretion, resulting in targeted killing of CLDN18.2-positive gastric and pancreatic cancer cells.